LIXTE Raises $11M, Expands LB-100 Trial to 42 Patients and Acquires Proton Therapy Firm
LIXTE filed its 2025 Form 10-K detailing a new leadership team led by CEO Geordan Pursglove, CFO Peter Stazzone and headquarters relocation to Boca Raton. It raised over $11 million, expanded LB-100 trial enrollment to 42 patients with a Northwestern site, and acquired Liora Technologies Europe for proton therapy innovation.
1. Annual Report Filing and Leadership Changes
LIXTE filed its 2025 Form 10-K, highlighting the appointment of Geordan Pursglove as Chairman, CEO and President, Peter Stazzone as CFO, and the addition of four new board members. The company also relocated its corporate headquarters to Boca Raton to support its strategic growth initiatives.
2. Clinical Trial Progress and Collaborations
LIXTE expanded enrollment of its lead compound LB-100 trial from 21 to 42 patients, added the Robert H. Lurie Comprehensive Cancer Center at Northwestern University as a second site, and deepened collaboration with MD Anderson Cancer Center and GSK for ongoing combination studies.
3. Capital Raise and Strategic Acquisition
During 2025, LIXTE raised more than $11 million through two registered direct offerings and a private placement to strengthen its balance sheet. In November, it acquired Liora Technologies Europe Ltd., securing the LiGHT System for electronically controlled proton therapy to diversify its cancer treatment platform.